SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0000950170-24-034351
Filing Date
2024-03-21
Accepted
2024-03-20 19:25:32
Documents
177
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 20-F/A sndl-20221231.htm   iXBRL 20-F/A 4143376
2 EX-12.1 CEO sndl-ex12_1.htm EX-12.1 4920
3 EX-12.2 CFO sndl-ex12_2.htm EX-12.2 4947
4 EX-13.1 CEO sndl-ex13_1.htm EX-13.1 4518
5 EX-13.2 CFO sndl-ex13_2.htm EX-13.2 8534
6 EX-15.1 MARCUM CONSENT sndl-ex15_1.htm EX-15.1 5733
7 GRAPHIC img148494503_0.jpg GRAPHIC 4464
  Complete submission text file 0000950170-24-034351.txt   22589474

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT sndl-20221231.xsd EX-101.SCH 3436778
181 EXTRACTED XBRL INSTANCE DOCUMENT sndl-20221231_htm.xml XML 5417520
Mailing Address 919 11 AVENUE SW SUITE 300 CALGARY A0 T2R1P3
Business Address 919 11 AVENUE SW SUITE 300 CALGARY A0 T2R1P3 14039485227
SNDL Inc. (Filer) CIK: 0001766600 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A0 | Fiscal Year End: 1231
Type: 20-F/A | Act: 34 | File No.: 001-39005 | Film No.: 24769051
SIC: 2833 Medicinal Chemicals & Botanical Products
(CF Office: 03 Life Sciences)